# A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients

> **NCT04890509** · PHASE2 · COMPLETED · sponsor: **BerGenBio ASA** · enrollment: 115 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Bemcentinib
- **OTHER:** SoC

## Key facts

- **NCT ID:** NCT04890509
- **Lead sponsor:** BerGenBio ASA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-20
- **Primary completion:** 2021-05-25
- **Final completion:** 2021-05-25
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04890509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04890509, "A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04890509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*